When Should You Stop Wegovy — and What Does the Evidence Say?

The 5% rule: where official stopping guidance actually comes from

The 5%-at-six-months benchmark isn't an arbitrary target. It comes directly from the NICE technology appraisal TA875, which assessed semaglutide for weight management in adults and built a continuation criterion into its recommendations: if a patient hasn't shed at least 5% of their body weight after six months on the maintenance dose, NICE recommends reconsidering treatment. This criterion exists because the medicine works for most people in that window, and where it hasn't, the benefit-to-burden balance shifts.

What counts as the 'maintenance dose' matters here. The titration schedule runs from 0.25 mg up through 0.5 mg, 1.0 mg, 1.7 mg and then 2.4 mg, with roughly four weeks at each level. The six-month clock for the 5% assessment runs from when you reach your highest tolerated dose, not from your very first injection. If you're unsure about the right time to begin, our guidance on when to start Wegovy covers how eligibility, timing, and dose progression all fit together. If you're still working up through doses at the six-month mark, that context should be part of the conversation with your prescriber.

Beyond the 5% rule, NICE's TA875 sets a two-year ceiling for NHS-funded semaglutide within specialist weight management services. Private prescribing follows individual clinical review rather than an automatic cut-off, but the same evidence base applies: a prescriber should reassess regularly, not simply renew indefinitely without considering progress.

What happens to weight when you stop, the STEP 1 extension data

One of the most important things to understand before deciding to stop Wegovy is what the trial evidence shows about what happens afterwards. The STEP 1 extension study, published in the New England Journal of Medicine, found that participants who stopped semaglutide after 68 weeks regained most of the weight they had lost within about a year, on average, roughly two-thirds of the reduction was reversed within 12 months of stopping. Cardiometabolic risk markers that had improved also largely returned to baseline.

This doesn't mean stopping is wrong. It means stopping without a plan is where most difficulty arises. The appetite-regulating effects of semaglutide are pharmacological: they ease while the medicine is active and wear off when it isn't. Biology, not willpower, drives what happens next. For many people, the question isn't simply 'when should I stop Wegovy' but 'what does stopping look like practically, and what support is in place', and our page on when to stop Wegovy works through exactly those considerations. That's a clinical conversation, not a solo calculation.

If you're thinking about whether Wegovy is right for you in the first place, understanding the stopping landscape is a reasonable part of that decision.

Medical reasons to pause or stop before the six-month review

The evidence-based 5% benchmark covers planned, elective stopping. There are also clinical situations where stopping Wegovy earlier is the right call, regardless of weight-loss progress. These include:

Pregnancy, trying to conceive, or breastfeeding. Semaglutide is not recommended during any of these. Prescribers typically advise stopping treatment and allowing a wash-out period before trying to conceive, the exact timing is confirmed with your prescriber and detailed in the Patient Information Leaflet.

Persistent side effects that don't resolve. GI symptoms (nausea, vomiting, diarrhoea) are most common when doses increase and usually settle. If they don't, dose adjustment or stopping may be appropriate. Severe, persistent abdominal pain that reaches the back should prompt urgent medical attention (this can be a sign of pancreatitis, which is a known but infrequent risk highlighted in an MHRA Drug Safety Update in January 2026).

Planned surgery. Tell your surgical team and anaesthetist that you're taking semaglutide before any procedure, your prescriber may advise pausing ahead of the date.

Questions about timing around lifestyle events (a holiday where the pen needs to travel, or a month where picking up a refill around payday is genuinely tricky) are exactly the kind of thing the practical dosing guidance and your prescriber's aftercare support are there for. It's also worth reading up on when to take semaglutide, which explains how day-to-day timing choices can affect tolerability and consistency.

Private prescribing, ongoing review and what to expect at nume

If you're accessing semaglutide privately rather than through an NHS specialist service, the two-year NICE ceiling doesn't apply as a hard rule, but responsible private prescribing still treats every repeat as an opportunity to reassess, not a formality. A prescriber should be looking at progress, any emerging side effects, your goals, and whether treatment remains appropriate.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it's approved. There's no auto-renewal. That structure exists precisely because stopping (or adjusting) is as important a clinical decision as starting. Our clinical team applies current UK guidance at each review, which means if your progress plateaus or your circumstances change, that conversation happens, not at an annual appointment, but at each repeat.

If you want a clearer picture of where you'd sit clinically before committing to anything, checking your eligibility through a free consultation is the practical first step.

You can also read more about how Wegovy works or explore the broader range of weight-loss treatments to understand the full clinical picture before deciding.